Revolution Medicines to Present New Preclinical Data from RAS(ON) Inhibitor Programs at AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics

Rhea-AI Summary

Revolution Medicines announced an invited oral presentation at the upcoming AACR-NCI-EORTC Virtual International Conference, showcasing preclinical data from its RAS(ON) inhibitor programs. Scheduled for October 9, 2021, the session will feature Steve Kelsey, M.D., presenting on the discovery and development of RAS(ON) inhibitors targeting various oncogenic RAS variants. This highlights the company's ongoing efforts in developing targeted therapies for RAS-addicted cancers.

Positive

• Company invited to present at prestigious cancer conference.
• New preclinical data to be shared, indicating progress in RAS(ON) inhibitor programs.
• Focus on novel therapies targeting RAS-driven cancers demonstrates innovation.

Negative

• None.

Company Invited to Deliver Oral Presentation in “Drugging Difficult Targets” Plenary Session

REDWOOD CITY, Calif., Sept. 30, 2021 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company focused on developing targeted drugs to inhibit frontier targets that drive and sustain RAS-addicted cancers, today announced that new preclinical data from several of the company’s RAS(ON) inhibitor programs will be reported in an invited oral presentation during a plenary session of the upcoming AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics being held October 7-10, 2021.

Details of the upcoming oral presentation at the AACR-NCI-EORTC conference are as follows:

• Title: Discovery and Development of RAS(ON) Inhibitors Beyond KRAS^G12C
  
  
• Presenter: Steve Kelsey, M.D., president, research and development
  
  
• Session: Plenary Session 5: Drugging Difficult Targets
  
  
• Session Date/Time: Saturday, October 9, 2021, 12:05 – 1:55 p.m. Eastern
  
  
• Session Panel Discussion: To follow completion of Plenary Session 5 presentations
  

To access a copy of the presentation slides, please visit the “Events & Presentations” page of Revolution Medicines’ website at https://ir.revmed.com/events-and-presentations. The presentation slides will be available on the “Events & Presentations” page of the Revolution Medicines website for at least 14 days following the conference.

Additional information on the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutic is available through the conference website at https://www.aacr.org/meeting/aacr-nci-eortc-international-conference-on-molecular-targets-and-cancer-therapeutics/

About Revolution Medicines, Inc.

Revolution Medicines is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit high-value frontier targets in RAS-addicted cancers. The company possesses sophisticated structure-based drug discovery capabilities built upon deep chemical biology and cancer pharmacology know-how and innovative, proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites.

The company’s R&D pipeline comprises RAS(ON) Inhibitors designed to suppress diverse oncogenic variants of RAS proteins, and RAS Companion Inhibitors for use in combination treatment strategies. RAS(ON) Inhibitors in development include RMC-6291, RMC-6236, and a pipeline of research compounds targeting additional RAS variants. RAS Companion Inhibitors in development include RMC-4630, RMC-5552, and RMC-5845.

FAQ

What will Revolution Medicines present at the AACR-NCI-EORTC conference?

Revolution Medicines will present new preclinical data from its RAS(ON) inhibitor programs.

When is Revolution Medicines' presentation scheduled?

The presentation is scheduled for October 9, 2021, from 12:05 to 1:55 p.m. Eastern Time.

Who is presenting the data for Revolution Medicines?

The data will be presented by Steve Kelsey, M.D., the president of research and development.

What is the focus of the RAS(ON) inhibitors developed by Revolution Medicines?

The RAS(ON) inhibitors aim to target various oncogenic variants of RAS proteins, which are critical in RAS-addicted cancers.

Where can I find the presentation slides from Revolution Medicines?

The presentation slides will be available on the Events & Presentations page of Revolution Medicines' website for at least 14 days following the conference.